-
-
-
-
-
-
-
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026
-
-
-
-
-
-
-
Harrow Announces First Quarter 2026 Financial Results
-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Harrow Health (HROW)
-
-
-
-
-
-
-
ImprimisRx Announces Leadership Changes
-
-
-
-
-
-
-
Harrow Announces Second-Quarter 2025 Financial Results
-
-
-
-
-
-
-
Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients
-
-
-
-
-
-
-
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
-
1,188,044 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

